Navigation Links
Jeffrey H. Buchalter Joins MacroGenics Board of Directors as Chairman
Date:9/26/2007

ROCKVILLE, Md., Sept. 26 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company's Board of Directors. With more than 20 years of experience in product development and commercialization in the pharmaceutical and biotechnology industry, Mr. Buchalter is well poised to work with the management team at MacroGenics as the company matures toward commercializing its pipeline.

"We are honored that Mr. Buchalter, an established leader in the biotechnology and pharmaceutical industry, has joined the MacroGenics Board of Directors as Chairman. His proven skills in building and transitioning research and development-based organizations into commercial enterprises will be a tremendous asset to MacroGenics," commented Scott Koenig, M.D., Ph.D., President and CEO.

"I am excited to have an opportunity to work closely with such a talented management team and esteemed group of investors and directors at MacroGenics," said Mr. Buchalter. "The company has done a terrific job in creating one of the best programs in monoclonal antibody therapeutics with its rich pipeline, platforms, and product development capabilities."

Mr. Buchalter currently serves as President, CEO and Chairman of the Board of Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN), a biopharmaceutical company dedicated to the development and commercialization of therapeutics for cancer and other life-threatening diseases. Prior to joining Enzon, Mr. Buchalter was President and Chief Executive Officer of ILEX Oncology, Inc., where he led the company's evolution from a contract research organization to a product- driven pharmaceutical company, with a high quality oncology franchise and established commercialization expertise. During Mr. Buchalter's tenure at ILEX, the company was acquired by Genzyme Corporation for $1.1 billion.

Mr. Buchalter also has held leadership roles at Pharmacia Corporation, Wyeth and Schering-Plough Corporation and has received awards for his commitment to the field of cancer research and development. In particular, he received the American Cancer Society's Joseph F. Buckley Memorial Award and was invited by former President George Bush to serve as a collaborating partner in the National Dialogue on Cancer. Mr. Buchalter received his B.S. in finance from Seton Hall University and a MBA in marketing from Temple University.

About MacroGenics, Inc.

Founded in 2000, MacroGenics is a private, venture-backed biotechnology company headquartered in Rockville, Maryland that focuses on the development, manufacture, and commercialization of immunotherapeutics for autoimmune disorders, cancer and infectious diseases. The company recently began Phase 3 clinical development of teplizumab with its Protg study (http://www.protegediabetes.org) to evaluate the potential of the monoclonal antibody to treat patients with new-onset juvenile diabetes and Phase 1 clinical development of another antibody to treat West Nile virus infections. The company's proprietary Fc engineering technology offers means to improve antibody function, such as enhancing the antibody's ability to eliminate cancer cells, cells that contribute to autoimmune disorders, or those infected with certain pathogens. For more information about MacroGenics, please visit http://www.macrogenics.com.

Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward- looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, and risks related to the Company's ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law.


'/>"/>
SOURCE MacroGenics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. WTN interview: Dr. Jeffrey Grossman, CEO UW Medical Foundation
2. Chemical-petroleum executive joins Virent Energy board
3. Schneider National exec joins TrafficCast board
4. Doyle joins governors in support of stem cell bill
5. Genomics researcher Hood joins NimbleGen board
6. Fergus joins Baird Venture Partners, Caden Bio
7. Meier joins Broadlook Technologies as COO
8. Prodesse joins forces with Invitrogen
9. Wisconsin joins price-fixing suit vs. D-RAM makers
10. Napier joins board of Third Wave Technologies
11. Schmidt rejoins Renaissance Learning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017  HUYA Bioscience International, ... China,s pharmaceutical innovations, announced today ... Sciences Innovation and Investment Company (referred to as CAS ... biomedical innovations discovered by leading scientists at CAS to ... HUYA is the first company to have ...
(Date:1/18/2017)... , Jan. 18, 2017 /PRNewswire/ - SQI Diagnostics ... and diagnostics company that develops and commercializes proprietary ... or the "Company"), today announced that Cameron ... ("Kingsdale"), has resigned from its Board of Directors.  ... to securities regulations that have limited both his ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Factor (RF) to its VALIDATE® SP2 calibration verification / linearity test kit. VALIDATE® ... serum base. Each VALIDATE® SP2 kit is prepared using the CLSI recommended “equal ...
(Date:1/17/2017)... NEW YORK , Jan. 17, 2017 /PRNewswire/ ... to grow at a CAGR of around 7.5% ... billion by 2025. Some of the prominent trends ... population, growing incidences of diseases & graft transplant ... Based on Material the market is categorized into ...
Breaking Biology Technology:
(Date:1/18/2017)... 2017 MedNet Solutions , an ... entire spectrum of clinical research, is proud to ... for the organization in terms of corporate growth, ... products and services. The company,s exceptional achievements can ... iMedNet ™ – ...
(Date:1/11/2017)... Iowa , Jan. 11, 2017 Intoxalock, ... first with the release of its patent-pending calibration device. ... and reliably perform calibrations, securely upload data logs and ... for the customer. "Fighting drunk driving through ... for the public at large, but also for the ...
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):